This EASL Studio showcases cutting-edge research elucidating the role of the liver in ageing and exploring its role as a regulator of health and longevity. In particular, the liver’s function in modulating systemic ageing, its ability to buffer genetic and metabolic disturbances, and its influence on the progression of age-related diseases is discussed. Last but not least, panelists provides new insights into potential therapeutic strategies aimed at promoting healthy ageing by targeting liver-specific mechanisms.

This episode is related to this study published in July 2024: Inhibition of IL-11 signalling extends mammalian healthspan and lifespan

Faculty:

• Rui Castro (Moderator)
• Anna Mae Diehl (Faculty)
• Celia Martinez-Jiménez (Faculty)

Related episode

• EASL Studio S7E8: Sarcopenia: Converting research findings into clinical practice – Are we doing enough?

All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio episode examines the current relevance of Hepatic Encephalopathy (HE) and the roles of hepatologists and interventional radiologists in patient care. The discussion covers technical approaches, patient outcomes, and the expanding indications for TIPS.

Tune in to:

• Learn about the critical roles of hepatologists and radiologists in managing HE.
• Understand technical factors, including TIPS procedures and their application in modern hepatology.
• Explore the use of TIPS for aging patients, those with variceal bleeding, and major surgery candidates.

Faculty

• Virginia Hernández-Gea (Moderator)
• Dominique Thabut (Faculty)
• Dhiraj Tripathi (Faculty)
• Thomas Kröncke (Faculty)

This EASL Studio is supported by an educational grant from Cook Medical. EASL has received no input from Cook Medical with regards to the content of this programme.

Related episodes

• EASL Studio S6E11: Assessment of clinically significant portal hypertension in 2024 – Is it time to say goodbye to invasive measurements?
• EASL Studio S2E14: Elastography – The new non-invasive gold standard in portal hypertension?

All EASL Studio Podcasts are available on EASL Campus.

Sarcopenia, defined by a reduction in muscle mass and strength, significantly increases the risk of hospitalisation and mortality in patients with liver cirrhosis. This EASL Studio episode highlights the importance of incorporating sarcopenia assessment and management into routine clinical practice. Experts discuss the optimal timing for assessment and strategies for implementing effective interventions.

Faculty

• Felicity Williams (Moderator)
• Shelley Keating (Faculty)
• Jennifer Lai (Faculty)
• Jonathan Stine (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio episode explores how alcohol worsens liver disease in patients with cardiometabolic risks, the stigma affecting diagnosis and care, and the latest therapeutic advances.

Key topics of discussion include:

• Interaction between alcohol and cardiometabolic risks
• Stigma and its impact on patient care
• Identifying at-risk patients with clinical markers
• Emerging therapies and research opportunities

Faculty

• Aleksander Krag (Moderator)
• Fredrik Åberg (Faculty)
• Maru Rinella (Faculty)
• Maja Thiele (Faculty)

This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input from Boehringer Ingelheim with regards to the content of this programme.

Related episodes

• EASL Studio S5E9: Alcohol and the new nomenclature – A game-changer?
• EASL Studio S4E8: The central role of alcohol and food policies on liver health
• EASL Studio S4E3: A 360 approach to beat alcohol-related liver disease
• EASL Studio S3E5: JHEP Live: Stigma and alcohol

All EASL Studio Podcasts are available on EASL Campus.

Join the experts as they explore the new updates to the liver transplantation clinical practice guidelines, and delve into the latest advancement and ongoing challenges faced in this field.

Tune in to:

• Discover cutting-edge techniques like machine perfusion and extended criteria grafts.
• Learn about new transplant indications, including oncology and acute liver failure.
• Understand challenges in immunosuppression and the management of chronic rejection.

Faculty

• Ahmed Elsharkawy (Moderator)
• Didier Samuel (Faculty)
• Julie Heimbach (Faculty)
• Sarwa Darwish (Faculty)

Related episodes

• EASL Studio S4E13: JHEP Live: Liver transplantation for alcohol-related hepatitis
• EASL Studio S4E6: Regenerating the liver graft with a machine
• EASL Studio S3E2: Liver transplantation for ACLF: Opportunities, challenges, and pitfalls
• EASL Studio S3E8: Transplanting patients with cancer – Is there a limit?

All EASL Studio Podcasts are available on EASL Campus.

This episode is organised in collaboration with the Healthy Livers, Healthy Lives Coalition.

Faculty

• Jeffrey Lazarus (Moderator)
• Mazen Noureddin (Faculty)
• Shira Zelber-Sagi (Faculty)
• Kremlin Wickramasinghe (Faculty)

The Healthy Livers, Healthy Lives Coalition’s activities are supported by Boehringer Ingelheim, Echosens, MSD, and Novo Nordisk.

Our industry partners have had no input into the content of the Health Livers, Healthy Lives Coalition’s activities or this EASL Studio episode.

Related episodes

• EASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscape
• EASL Studio S6E7: The impact of policy measure in preventing liver diseases: The Hepahealth II study
• EASL Studio S6E1: Do we solve MASLD by treating obesity?
• EASL Studio S5E2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathways
• EASL Studio S4 Special Edition 2: Promoting Liver Health: An urgent call for action at WHO
• EASL Studio S4E8: The central role of alcohol and food policies on liver health

All EASL Studio Podcasts are available on EASL Campus.

This episode explores the latest developments in liver disease, with a focus on metabolic-associated steatotic liver disease (MASLD) and its impact on liver cancer, particularly hepatocellular carcinoma (HCC). The main focus is the emerging role of advanced imaging technologies. The discussion:

• Compares traditional ultrasound with advanced imaging techniques.
• Examines AI-based approaches in patient classification.

The episode concludes with a forward-looking perspective on the future management of MASLD.

Faculty

• Thomas Berg (Moderator)
• Timm Denecke (Faculty)
• Juan-Manuel Pericàs (Faculty)
• Valérie Vilgrain (Faculty)

This EASL Studio is supported by Bayer. EASL has received no input from Bayer with regards to the content of this programme.

Related episodes

• EASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscape
• EASL Studio S6E1: Do we solve MASLD by treating obesity?
• EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance

All EASL Studio Podcasts are available on EASL Campus.

Renal dysfunction is a significant concern for patients with liver cirrhosis, affecting nearly 50% of those hospitalised and leading to various complications that can reduce survival rates. Recently, the diagnostic criteria for acute kidney injury (AKI) and hepatorenal syndrome (HRS) have been updated to better capture the diversity and incidence of these conditions in cirrhotic patients.

This episode of EASL Studio:

• Explores the updated definitions and standardisation of AKI in the context of cirrhosis.
• Reviews recent clinical trials, including ATTIRE and CONFIRM, and their implications for patient care.
• Provides a critical analysis of current and emerging strategies for managing renal dysfunction in cirrhosis.

Faculty

• Debbie Shawcross (Moderator)
• Pere Gines (Faculty)
• Salvatore Piano (Faculty)
• Florence Wong (Faculty)

Related episodes

• EASL Studio from EASL Congress 2024: Deciphering the drivers of cirrhosis decompensation: Opportunities for intervention and prevention
• EASL Studio S6E8: Is there a role for measuring blood ammonia in patients with cirrhosis?
• EASL Studio S6E5: JHEP Live: Should the compensated advanced chronic liver disease (cACLD) concept replace cirrhosis?
• EASL Studio S5E11: Statins in cirrhosis: The window hypothesis again, or just a closed window?
• EASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address them
• EASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?

This episode is sponsored by Mallinckrodt Pharmaceuticals. Mallinckrodt Pharmaceuticals have had no input into the content of this EASL Studio episode.

All EASL Studio Podcasts are available on EASL Campus.